| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 5.467 | 5.411 | 7.093 | 6.963 | 6.828 | 6.698 | 6.550 | 6.570 | - | - |
| Total Income - EUR | 5.467 | 5.411 | 7.093 | 6.963 | 6.828 | 6.698 | 6.550 | 6.570 | - | - |
| Total Expenses - EUR | 1.658 | 2.081 | 924 | 0 | 6.322 | 11.370 | 5.345 | 1.463 | - | - |
| Gross Profit/Loss - EUR | 3.809 | 3.330 | 6.168 | 6.963 | 506 | -4.672 | 1.204 | 5.107 | - | - |
| Net Profit/Loss - EUR | 3.591 | 3.114 | 5.956 | 6.754 | 301 | -4.873 | 1.008 | 4.910 | - | - |
| Employees | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | - | - |
Check the financial reports for the company - Gadel - Profarm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 10.304 | 10.199 | 10.027 | 9.843 | 9.652 | 9.469 | 9.259 | 9.288 | - | - |
| Current Assets | 25.322 | 15.566 | 12.256 | 18.746 | 18.684 | 13.457 | 14.166 | 13.645 | - | - |
| Inventories | 1.101 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Receivables | 21.036 | 13.510 | 11.158 | 11.993 | 11.760 | 11.537 | 12.962 | 13.002 | - | - |
| Cash | 3.186 | 2.057 | 1.098 | 6.754 | 6.924 | 1.919 | 1.204 | 643 | - | - |
| Shareholders Funds | 34.665 | 24.694 | 22.283 | 28.589 | 28.336 | 22.926 | 23.425 | 22.933 | - | - |
| Social Capital | 45 | 45 | 4.838 | 4.749 | 4.657 | 4.569 | 4.468 | 4.481 | - | - |
| Debts | 961 | 1.072 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
6820
|
|||||||||
Comments - Gadel - Profarm S.r.l.